Group 1: Haoyuan Pharmaceutical - Haoyuan Pharmaceutical emphasizes technological innovation as its core competitiveness, with plans to invest in R&D across multiple fields including anti-tumor and anti-viral areas in 2024 [1] - The company has completed the construction of a solid-phase platform for peptides, establishing a peptide CRO capability and developing over 600 compounds, along with a peptide drug production platform in Ma'anshan [1] - The molecular building block business is projected to achieve revenue of 420 million yuan in 2024, representing a year-on-year growth of 35.7%, with a reserve of 92,000 types of molecular building blocks and capabilities in customized R&D and global supply chain management [1] - Progress has been made in the construction of industrialization and CDMO bases in Jiangsu Qidong, Shandong Heze, Anhui Ma'anshan, and Chongqing, with some workshops already in operation [1] Group 2: Aladdin - Aladdin has achieved strong competitiveness through independent research and innovation, with several products realizing domestic substitution [2] - The company collaborates closely with Yuan Ye and Feipeng to share resources, expand business scale, and enhance overall competitiveness [2] - Cost control measures include promoting convertible bond conversions, optimizing inventory turnover, expanding overseas markets, and developing the biological reagent business [2] - Revenue growth in the life sciences segment is primarily driven by the merger with Yuan Ye Bio, which has increased sales of major life science products [2] - Both external and internal growth strategies are driving the company's development, with active research into potential acquisition projects [2] Group 3: Company Overview - Shanghai Panyao Asset Management Co., Ltd. was established on December 4, 2014, with a registered capital of 10 million yuan and holds a private equity license [3] - The firm focuses on long/short equity strategies and has issued over 100 products, with a cumulative registered scale exceeding 5 billion yuan [3] - Panyao Asset aims to manage financial wealth sustainably, emphasizing research-driven investment and a rigorous investment process [3] - The company seeks an ideal combination of top-down macro and industry allocation with bottom-up company selection in its investment strategy [3]

Group 1: Shanghai Jahwa - Shanghai Jahwa is confident about achieving high double-digit GMV growth for its core brands during the 618 shopping festival [1] - The employee stock ownership plan aims to enhance competitiveness, reduce turnover, and foster a sense of ownership among employees [1] - Recent strategic adjustments include clarifying strategy, aligning organizational design, building talent teams, and cultural development [1] - E-commerce initiatives involve inventory optimization, pricing adjustments, organizational restructuring, and product iteration [1] - The Yuze B5 series is planned as a key product line for JD.com [1] - The company aims for double-digit revenue growth this year and to turn profits around [1] - The long-term profit recovery is expected to follow a 1-2 year revenue growth, 2-3 year profit improvement, and 3-5 year profit margin targets [1] Group 2: Zai Lab - Zai Lab introduced its pipeline drugs ZG006, ZG005, and ZGGS18, highlighting their latest progress and future plans for R&D, commercialization, and internationalization over the next 3-5 years [2] - ZG006 is the world's first DLL3-expressing tumor tri-specific antibody, which has received clinical trial approval from NMPA and FDA, showing promising early efficacy [2] - ZG005 is among the first drugs in clinical research targeting the same pathway, with multiple clinical studies ongoing [2] - ZGGS18 has completed the I phase dose escalation in China and is currently in I/II phase clinical trials [2] - The company plans to continuously explore the commercialization potential of its existing and upcoming products to achieve sustained revenue growth [2] Group 3: Aladdin - Aladdin has achieved several domestic product replacements through independent R&D and innovation, enhancing its competitive edge [3] - The company collaborates with Yuan Ye and Fei Peng to share resources, expand business scale, and improve overall competitiveness [3] - Cost control measures include promoting convertible bond conversions, optimizing inventory turnover, and expanding overseas markets and biological reagent business [3] - Revenue growth in the life sciences sector is primarily driven by the merger with Yuan Ye Bio, increasing sales of major life science products [3] - Both external and internal growth strategies are driving the company's development, with active research into potential acquisition projects [3] Group 4: Company Overview - Shanghai Licheng Asset is one of the earliest established private equity management companies in China, focusing on growth stock investment with a safety margin approach [4] - The company has a complete and unique investment management knowledge system, with a team of 50 employees, nearly 30 of whom are professional research analysts [4] - The management scale has exceeded 10 billion yuan, specializing in secondary stock long strategies and PIPE strategies in the pharmaceutical, advanced manufacturing, and consumer sectors [4] - Licheng has consistently ranked high in long-term performance and has received multiple private equity awards [4]

上海阿拉丁生化科技股份有限公司 舆情管理制度 第一章 总则 第一条 为提高上海阿拉丁生化科技股份有限公司（以下简称"公司"）应 对各类舆情的能力，建立快速反应和应急处置机制，及时、妥善处理各类舆情 对公司股价、商业信誉及正常生产经营活动造成的影响，切实保护投资者合法 权益，根据相关法律法规、规范性文件和《上海阿拉丁生化科技股份有限公司 股份有限公司章程》（以下简称"公司章程"）等规定，制定本制度。 第二条 本制度所称舆情包括： （一）报刊、电视、网络等媒体对公司进行的负面报道； （二）社会上存在的已经或将给公司造成不良影响的传言或信息； （三）可能或者已经影响社会公众投资者投资取向，造成股价异常波动的 信息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生 较大影响的事件信息。 第二章 舆情管理的组织体系及其工作职责 第三条 公司应对各类舆情（尤其是媒体质疑危机时）实行统一领导、统一 组织、快速反应、协同应对。 第四条 公司舆情管理工作由公司董事会统一领导和管理，董事长作为第一 责任人，负责领导各类舆情处理工作。必要时可成立舆情管理应急小组，由董 事长任组长，董事会秘书任副组长，其他高级管理 ...

Summary of Aladdin's Conference Call Company Overview - Aladdin reported a revenue of 1.30 billion in 2024, a year-on-year increase of 32.2%, with a net profit of 23.81 million, growing by 41.9% [2][3] - The gross margin was 63.56%, and the net margin was 21.7%, slightly lower than the previous year [2][3] Financial Performance - In Q1 2025, Aladdin achieved a consolidated revenue of 1.30 billion, a 32.2% increase year-on-year, and a net profit of 2.38 million, up 41.9% [3] - The company faced losses from overseas subsidiaries and biotech R&D subsidiaries, impacting overall profits [3] - The company plans to reduce expenses in 2025 to improve profitability [2][5] Market Expansion - Aladdin is actively expanding into overseas markets, having signed an agency agreement with Merck in the U.S., increasing the number of distributors to 7 [2][6] - Orders surged after the entry of Aoko, with expectations to break even in 2025 [2][6] - The company is enhancing sales team capabilities and promotional efforts to accelerate inventory turnover and reduce inventory impairment provisions [2][6] Biotech Sector Investments - Aladdin is focusing on external investments in the biotech sector, collaborating with companies like Wuhan Jingxuan and Feipeng Bio to expand its product line [2][7] - A strategic partnership with Baitong aims to enhance R&D collaboration and improve development speed and efficiency [2][7] - The goal is to achieve profitability in the biotech reagent sector as soon as possible [2][7] Future Strategies - Key future tasks include significantly reducing inventory impairment provisions, interest expenses, and accelerating overseas market expansion and biotech reagent external expansion [2][8] - Even with low revenue growth, these measures are expected to significantly enhance profits [2][9] Impact of Competitors and Market Conditions - Orders increased by approximately 10% month-on-month and 15%-20% year-on-year due to competitors' price hikes or product shortages [2][11] - The company signed a domestic agency agreement with Walker to accelerate domestic substitution [2][11] - Aladdin is actively expanding in Europe to mitigate fluctuations in the U.S. market [2][11] Cost Management - The company incurred approximately 9.4 million in asset impairment losses, 1 million in credit impairment losses, and 7.2 million in interest expenses [4] - Cost control measures are in place, including promotional activities to alleviate inventory pressure and actively promoting convertible bond conversions to reduce interest expenses [19][20] Collaboration and Product Development - Aladdin's collaboration with Yamei Bio is expected to enhance its biotech reagent business, with Yamei's annual sales exceeding 50 million and profits nearing 10 million [4][14] - The company is also working closely with partners like Yuanying and Feipeng to develop new products and improve product quality [18] Market Trends and Challenges - The U.S. tariff policies are affecting the research reagent industry, with potential impacts on competition [10][30] - The domestic market is seeing a shift towards local brands due to high import tariffs, which is accelerating the substitution process [11][30][37] Investment Strategy - Aladdin's investment strategy focuses on expanding its product line, particularly in the biotech sector, with plans for acquisitions in the second half of the year [24][36] - The company aims to achieve a net profit margin of 35% in the medium term, with expectations for improved profitability as operational efficiencies are realized [22][36] Conclusion - Aladdin is positioned for growth through strategic market expansion, cost management, and collaboration in the biotech sector, despite facing challenges from competitors and market conditions. The focus on reducing expenses and enhancing product offerings is expected to drive profitability in the coming years [2][36]

三、本次归属的具体情况 （一）授予日：2021年12月7日。 （四）授予价格（调整后）：13.99元/股（因公司2021年度权益分派，授予价格由40元/股调整为28.29 元/股；因公司2022年度权益分派，授予价格由28.29元/股调整为20.03元/股，因公司2023年度及2024前 三季度权益分派，授予价格由20.03元/股调整为13.99元/股）。 （五）股票来源：公司向激励对象定向发行公司A股普通股股票。 （六）激励对象名单及归属情况 登录新浪财经APP 搜索【信披】查看更多考评等级 综上，2021年限制性股票激励计划首次授予部分第三个归属期合计78名激励对象可归属32.6968万股限 制性股票。 （三）监事会意见 监事会认为：根据《上市公司股权激励管理办法》《2021年限制性股票激励计划》的相关规定，公司 2021年限制性股票激励计划首次授予部分第三个归属期归属条件已经成就。因此，监事会同意公司依据 2021年第二次临时股东大会的授权并按照公司《2021年限制性股票激励计划》的相关规定为符合归属条 件的78名激励对象办理归属32.6968万股限制性股票的相关事宜。 ■ 四、监事会对激励对象名单的核 ...

上海阿拉丁生化股份有限公司 2024年度独立董事述职报告(黄遵顺) 作为上海阿拉丁生化科技股份有限公司(以下简称"公司")的独立董事, 2024 年度本人严格按照《公司法》、《证券法》、《上市公司治理准则》、《上 市公司独立董事管理办法》、《公司章程》和《独立董事工作制度》等相关法律、 法规、规章的规定和要求,诚实、勤勉、独立的履行职责,积极出席相关会议, 认真审议董事会各项议案,对公司重大事项发表了独立意见,切实维护公司和股 东的合法权益,促进公司规范运作,充分发挥了独立董事及各专门委员会的作用。 现将本人在 2024年度履行独立董事职责的情况报告如下; 一、独立董事的基本情况 (一)个人工作履历、专业背景以及兼职情况 黄遵顺先生:1970年3月出生,中国国籍,无境外永久居留权,硕士研究生学 历,高级会计师。2007年7月至2015年5月,任上海中卡智能卡有限公司财务部 经理;2015年6月至2016年7月,任上海美迪西生物医药股份有限公司财务部经 理:2016年8月至2017年9月,任上海瞪羚众创空间管理股份有限公司财务总监; 2017年10月至2018年9月,任上海瞪羚众创空间管理股份有限公司董事、总经 ...

作为上海阿拉丁生化科技股份有限公司(以下简称"公司")的独立董事, 2024 年度本人严格按照《公司法》、《证券法》、《上市公司治理准则》、《上 市公司独立董事管理办法》、《公司章程》和《独立董事工作制度》等相关法律、 法规、规章的规定和要求,诚实、勤勉、独立的履行职责,积极出席相关会议, 认真审议董事会各项议案,对公司重大事项发表了独立意见,切实维护公司和股 东的合法权益,促进公司规范运作,充分发挥了独立董事及各专门委员会的作用。 现将本人在 2024年度履行独立董事职责的情况报告如下; 一、独立董事的基本情况 (一)个人工作履历、专业背景以及兼职情况 吕顺辉先生:1982年10月出生,中国国籍,无境外永久居留权,硕士研究生学 历。2008年 8 月至 2010 年 10 月，任上海久隆企业管理咨询有限公司项目经理; 2010 年 11 月至 2013 年 12 月,任上海富厚股权投资有限公司投资总监;2014 年 1 月至 2017 年 5 月，任上海朗程投资管理有限公司副总裁; 2022 年 5 月至 2022 年 8 月,任上海普丽盛包装股份有限公司独立董事;2015年 10 月至今,任上海朗毅信 息 ...

上海阿拉丁生化股份有限公司 2024年度独立董事述职报告(孙佳) 作为上海阿拉丁生化科技股份有限公司(以下简称"公司")的独立董事, 2024 年度本人严格按照《公司法》、《证券法》、《上市公司治理准则》、《上 市公司独立董事管理办法》、《公司章程》和《独立董事工作制度》等相关法律、 法规、规章的规定和要求,诚实、勤勉、独立的履行职责,积极出席相关会议, 认真审议董事会各项议案,对公司重大事项发表了独立意见,切实维护公司和股 东的合法权益,促进公司规范运作,充分发挥了独立董事及各专门委员会的作用。 现将本人在 2024年度履行独立董事职责的情况报告如下; 一、独立董事的基本情况 (一)个人工作履历、专业背景以及兼职情况 报告期内,本人认真参与公司董事会各项会议,关注股东大会召开情况,本 着审慎客观的原则,以勤勉负责的杰度,认真审阅会议议案及其他相关材料,积 极参与各议案的讨论,最大限度发挥各自专业知识和工作经验的优势,提出合理 的意见和建议,同时独立、客观地行使表决权。报告期内,本人对公司董事会各 项议案及其它事项均投了赞成票,无提出异议的事项,也无反对、弃权的情形。 具体情况见下表: | | | | | 参 ...

| 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2025-037 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 关于注销部分募集资金专项账户的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 募集资金基本情况 根据中国证券监督管理委员会《关于同意上海阿拉丁生化科技股份有限公司 首次公开发行股票注册的批复》（证监许可【2020】2116 号），上海阿拉丁生化 科技股份有限公司获准向社会公众发行人民币普通股（A 股）2,523.34 万股，每 股发行价格 19.43 元，新股发行募集资金总额为人民币 49,028.50 万元，扣除发 行费用人民币 5,585.48 万元（不含增值税）后，实际募集资金净额为人民币 43,443.02 万元。 上述募集资金已全部到位，并由大华会计师事务所（特殊普通合伙）于 2020 年 10 月 22 日对本次发行的资金到账情况进行了审验，出具了《验资报告》（大 华验字【2020】00 ...

| 转债代码：118006 | 转债简称：阿拉转债 | | --- | --- | | 证券代码：688179 | 证券简称：阿拉丁 公告编号：2025-033 | 上海阿拉丁生化科技股份有限公司 关于 2025 年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 是否需要提交股东大会审议：否 日常关联交易对上市公司的影响：本次关联交易预计为公司及子公司与 其关联方日常发生的关联交易，是正常生产经营业务，以市场价格为定价依据， 遵循平等自愿原则，交易风险可控，不会对关联人形成较大的依赖，不影响公司 的独立性，不存在损害公司及股东利益的情况。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 1、独立董事专门会议审议情况 就本次日常关联交易预计事项，公司独立董事在董事会审议前召开了专门会 议，并一致审议通过了《关于 2025 年度日常关联交易预计的议案》。公司独立董 事认为：公司 2025 年度预计发生的日常关联交易事项为公司开展日常生产经营 所需，相关交易遵循协商一致、公 ...